Drug maker Golden Biotechnology Corp (國鼎生技) yesterday said that its new lung cancer drug has received approval from the US Food and Drug Administration (FDA) to enter second-stage clinical trials, paving the way for the medicine to hit the world market in 2017.
Hocena is the first chemical drug developed by the company. It has a higher profit margin than the other botanical drugs in the pipeline, the company said.
The company yesterday signed an agreement to outsource the second-phase clinical trials to global contract research organization Icon Holdings Corp. Icon will conduct the trials in the US and Taiwan first, based on the agreement.
Golden Biotechnology plans to spend US$10 million on clinical trials, company chairman Alex Liu (劉勝勇) told a media briefing yesterday.
“We expect the drug to hit the market within 20 months, as the US government has allowed the drug to enter the fast track,” meaning it can skip third-phase clinical trials, he said.
There is currently no drug that can cure lung cancer, but the new approach offered by Hocena to treat the disease could give new hope to lung cancer patients, Liu said.
OTHER CANCER TYPES
Aside from lung cancer, Golden Biotechnology also plans to test Hocena for treatment of pancreatic cancer, colorectal cancer and leukemia when the drug passes the first part of phase two clinical trials within the next six to 10 months, said Chen Chih-ming (陳志銘), director of the company’s research and development department.
The market for lung cancer and pancreatic cancer drugs is estimated at about US$6.5 billion a year, according to Golden Biotechnology. That is less than a 10th of the overall market for cancer drugs last year, at US$80 billion.
The company plans to expand its capital to about NT$1 billion (US$33.7 million) from NT$700 million now by the end of this year to fund the clinic trials.
Farglory Group (遠雄集團), which has a 20 percent stake in the company, is its largest shareholder, followed by three companies set up by Global Mixed-mode Technology Inc (致新科技) chairman Hsieh Nan-chiang (謝南強), which own 10 percent of the shares.
Golden Biotechnology expects to narrow its loss to NT$64.44 million in the first half of this year, from a loss of NT$83.39 million in the same period last year.
Chief financial officer Jackson Huang (黃士旗) said the company is unlikely to turn a profit by the end of next year because it has to spend money on clinical trials.
NOTABLE SHIFT: By 2030, 50% of all laptops would be assembled in Southeast Asia, while Taiwan would still mostly focus on research and development, a report said Global laptop and desktop computer supply chains are expected to shift significantly away from China in the next 10 years, a Market Intelligence & Consulting Institute (MIC, 產業情報研究所) report said. By 2030, only 40 percent of global laptop production would remain in China, said the report, which was released on Thursday. “The reshuffling of the global supply chain will be one of the most important trends in the next 10 years,” the institute said in the report. “In the long run, key component makers will follow laptop assemblers in moving out of China.” The Taipei-based institute predicted most key component makers
Merck Group Taiwan yesterday said that it plans to invest substantially on expanding its fab in Kaohsiung’s Lujhu District (路竹) to better serve its local customers, including Taiwan Semiconductor Manufacturing Co (TSMC, 台積電). The company said it plans to expand its production space by 50 percent in the next five years and its workforce by about 40 percent, Merck Group Taiwan managing director Dick Hsieh (謝志宏) told a media briefing in Taipei. Hsieh declined to disclose investment details, but said that the latest investment would exceed the total amount Merck has invested in Taiwan over the past few years. Those investments would be
INVEST IN TAIWAN: A metal components casting firm and the world’s largest maker of aluminum bicycle rims also obtained approvals to join the program Solar Applied Materials Technology Co (SOLAR, 光洋應用材料), a part of Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) “green supply chain,” has pledged to invest NT$1 billion (US$34.1 million) to build a new plant at the Tainan Technology Industrial Park (台南科技工業區), the Ministry of Economic Affairs said yesterday. SOLAR has been collaborating with TSMC to extract precious metals from waste and reuse them as “sputtering target” material in high-end semiconductor manufacturing, a TSMC press release issued in May said. Established in 1978, SOLAR also offers key materials and integrated services to customers in the optoelectronics, information and communications technology, petrochemicals and consumer electronics industries,
‘SWARM TECH’: Joint venture FARobot is to develop autonomous mobile robots that would first be deployed in Hon Hai’s factories to optimize production efficiency Hon Hai Precision Industry Co (鴻海精密) and Adlink Technology Inc (凌華科技) have formed a robotic venture that aims to use “swarm technology” to create robots that can communicate with one another on the factory floor to optimize production efficiency. Hon Hai is Apple Inc’s leading iPhone assembler and the world’s largest contract electronics maker, while Adlink supplies industrial computers and Internet of Things solutions. Through a subsidiary, Hyield Venture Capital Co (鴻揚創投), Hon Hai holds a 51 percent stake in autonomous mobile robot (AMR) developer FARobot (法博智能移動), while Adlink owns the remaining 49 percent. Together, the two companies put up NT$200